MedPath

Eplerenone

Generic Name
Eplerenone
Brand Names
Inspra
Drug Type
Small Molecule
Chemical Formula
C24H30O6
CAS Number
107724-20-9
Unique Ingredient Identifier
6995V82D0B
Background

Eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. The resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. Eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.

Indication

For improvement of survival of stable patients with left ventricular systolic dysfunction (ejection fraction <40%) and clinical evidence of congestive heart failure after an acute myocardial infarction.

Associated Conditions
Hypertension, LVEF <40% Congestive heart failure, Chronic heart failure with reduced ejection fraction (NYHA Class II)
Associated Therapies
-

Aldosterone Antagonism in Diastolic Heart Failure

Phase 4
Completed
Conditions
Congestive Heart Failure
Diastole
Interventions
Drug: Placebo
Drug: Eplerenone
First Posted Date
2005-04-15
Last Posted Date
2011-09-08
Lead Sponsor
US Department of Veterans Affairs
Target Recruit Count
48
Registration Number
NCT00108251
Locations
🇺🇸

Michael E DeBakey VA Medical Center, Houston, Texas, United States

The Purpose of This Study is to Determine if Eplerenone is Effective in Treatment of Mild to Moderate Heart Failure

Phase 4
Completed
Conditions
Heart Failure, Congestive
First Posted Date
2004-05-14
Last Posted Date
2020-12-22
Lead Sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Target Recruit Count
250
Registration Number
NCT00082589
Locations
🇺🇸

Pfizer Investigational Site, Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath